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Abstract
Background: Cisplatin has been in use for 40 years for treatment of germ line and other forms
of cancer. Oxaliplatin is approved for treatment of metastatic colorectal cancer. Thirty to forty
percent of cancer patients receiving these agents develop pain and sensory loss. Oxaliplatin induces
distinctive cold-associated dysesthesias in up to 80% of patients.
Results: We have established mouse models of cisplatin and oxaliplatin-induced neuropathy using
doses similar to those used in patients. Adult male C57BL6J mice were treated with daily
intraperitoneal injection for 5 days, followed by 5 days of rest, for two cycles. Total cumulative
doses of 23 mg/kg cisplatin and 30 mg/kg oxaliplatin were used. Behavioral evaluations included cold
plate, von Frey, radiant heat, tail immersion, grip strength and exploratory behavior at baseline and
at weekly intervals for 8 weeks. Following two treatment cycles, mice in the cisplatin and oxaliplatin
treatment groups demonstrated significant mechanical allodynia compared to control mice. In
addition, the cisplatin group exhibited significant thermal hyperalgesia in hind paws and tail, and the
oxaliplatin group developed significant cold hyperalgesia in hind paws.
Conclusion: We have therefore established a model of platinum drug-induced painful peripheral
neuropathy that reflects the differences in early thermal pain responses that are observed in
patients treated with either cisplatin or oxaliplatin. This model should be useful in studying the
molecular basis for these different pain responses and in designing protective therapeutic strategies.
Background
Cisplatin has had a central role in cancer chemotherapy
for the last 40 years [1,2] and continues to be among the
most widely-used antineoplastic drugs in clinical use
[3,4]. Cisplatin displays therapeutic efficacy in a broad
range of solid tumors especially against testicular, ovarian,
and bladder cancers [5,6]. It exerts its antitumor activity
by binding to DNA and distorting the helical structure in
a way that inhibits transcription [7] and induces apoptotic
cell death through DNA damage recognition pathways
[8,9]. Peripheral neuropathy remains the most common
dose limiting toxicity of cisplatin and limits its clinical use
[10,11]. Currently, no effective treatment is available to
prevent or treat chemotherapy-induced neuropathy [12].
Significant cisplatin neurotoxicity occurs when cumula-
tive dosage exceeds 300 mg/m2 to 400 mg/m2 [13-16],
and is predominantly characterized by sensory neuropa-
thy with initial complaints of pain and paresthesiae in the
distal extremities [17,18]. This sensory neuropathy may
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be delayed in onset, appearing weeks after initiation of
therapy. In advanced stages it may progress to severe neu-
ropathic pain and sensory ataxia. In nerve conduction
studies, the sensory loss is usually associated with reduc-
tion in the amplitude of sensory nerve action potentials,
reflecting axonal degeneration [17-21]. Long term cancer
survivors may experience residual pain that lasts for many
years [22].
Oxaliplatin is a third-generation diaminocyclohexane
(DACH) platinum drug that produces cold induced dys-
esthesia in 90% of patients. The drug is effective for meta-
static colorectal cancer [23-25], as well as ovarian and
pancreatic cancers [26,27]. Like cisplatin, it is known to
cross-link DNA. It is thought to have greater cytotoxic
effects than cisplatin because of the bulkier DACH-plati-
num-adducts [28,29]. Clinically, oxaliplatin induces
acute and chronic peripheral neuropathy [30,31]. In con-
trast to cisplatin, oxaliplatin induces acute neuropathy
consisting of cold-induced paraesthesia, dysesthesia or
pain in the upper limbs, face, and perioral regions. Symp-
toms develop early in treatment, typically during the first
or second cycle and occur regularly with each cycle of
treatment. Similar to cisplatin, about 20 to 30% of
patients develop chronic neuropathy with oxaliplatin
treatment after longer therapy due to a cumulative toxic-
ity, resulting in pain and loss of sensation.
Although there are distinct differences in the features of
the pain associated with platinum compounds, no study
has directly compared cisplatin and oxaliplatin in a single
animal model. We sought to establish a mouse model that
would resemble painful peripheral neuropathy in
humans and would be valuable for future elucidation of
pain mechanisms associated with cisplatin and oxalipla-
tin-induced neuropathy. The aim of this study was to
determine whether differences exist between cisplatin and
oxaliplatin-induced painful neuropathy in mice.
Results
Evaluation of general toxicity
All mice survived until the end of study with the exception
of one in the cisplatin group that died suddenly at the end
of week four. There was no evidence of severe general tox-
icity. In general, there was no alteration of body tempera-
ture and no deterioration in general health status of cis- or
oxaliplatin-treated mice compared to control mice.
All mice maintained grooming habits, had normal skin
texture on all paws and tail, and exhibited no signs of
autotomy. No significant difference of body weight was
observed at base line between mice in the three groups
(Fig. 1, P > 0.05, two-way ANOVA). However, there was a
significant decrease in mean body weight in the cisplatin
group compared to vehicle control after the first treatment
cycle (23.62 ± 0.73 g vs 26.66 ± 0. 49 g, (*P  < 0.05,
ANOVA); and after the second treatment cycle (22.76 ±
0.91 g vs 27.43 ± 0. 50 g, ***P < 0.001, ANOVA). While a
similar trend of weight reduction was seen in the oxalipl-
atin group after each treatment cycle, this difference was
not statistically significant compared to the controls (P >
0.05, ANOVA). Mice in both drug groups gradually
regained body weight and no significant difference in
mean body weight was present between groups after six
and eight weeks (Fig. 1, P > 0.05, ANOVA).
We observed no evidence of nephrotoxicity following
platinum drug treatment. In baseline measurement, prior
to drug treatment, blood urea nitrogen (BUN) values for
mice in the cisplatin, oxaliplatin, and control treatment
groups: 20 mg/dl, 24 mg/dl, and 24 mg/dl respectively.
After the 3-week treatment period BUN values were nor-
mal for cisplatin, oxaliplatin, and control treatment
groups; 27 mg/dl, 15 mg/dl, and 24 mg/dl respectively.
Cis- and oxaliplatin-treated mice exhibit less exploratory 
behavior following each treatment cycle
In various pain modality assays, significant differences
were observed in the paw lift response in mice following
platinum drug treatment. To rule out the possibility that
such variances were due to differences in overall activity
following drug treatment, we monitored mouse explora-
tory activity by measuring the horizontal distance traveled
in 30 min using Versamax Animal Activity Monitors.
Treatment with either cisplatin or oxaliplatin induced sig-
nificant attenuating effects in the levels of locomotor
activity in all mice but was much greater for cisplatin than
oxaliplatin.
Cisplatin-treated mice have reduced body weight after each  drug treatment cycle Figure 1
Cisplatin-treated mice have reduced body weight 
after each drug treatment cycle. Data represent the 
mean ± S.EM of 7 mice, *P < 0.05; ***P < 0.001, two-way 
ANOVA followed with post hoc analysis.Molecular Pain 2009, 5:9 http://www.molecularpain.com/content/5/1/9
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At baseline, there was no significant difference observed
in the mean locomotor activity or horizontal distance
traveled between mice for all groups (Fig. 2, P > 0.05, two-
way ANOVA). However, there was a significant decrease
in mean distance traveled by mice in the cisplatin group
compared to vehicle controls after the first treatment cycle
(119.52 ± 15.88 cm vs 319.92 ± 43.89 cm, (*P < 0.05,
ANOVA), and after the second treatment cycle (142.30 ±
28.10 cm vs 394.85 ± 61.93 cm, **P < 0.01, ANOVA). A
lesser reduction in mean distance traveled was also
observed after each treatment cycle in the oxaliplatin
group, but the decrease was not statistically significant (P
> 0.05, ANOVA). Mice in both drug groups gradually
returned to their normal exploratory behaviors and no
significant difference was observed in the mean horizon-
tal distance traveled in all groups at weeks six or eight (P
> 0.05, ANOVA). These data suggest that the observed
increases in responses to painful stimuli in the drug treat-
ment groups are not due to an overall increase in general
activity.
Cis- and oxaliplatin-treated mice maintain normal muscle 
strength
There was no effect of either drug on grip strength which
mimics the situation in platinum-treated patients who
develop a pure sensory neuropathy. At base line, no signif-
icant difference of grip strength was observed between
mice in the three groups (P > 0.05, two-way ANOVA).
Mean baseline grip strength for cisplatin, oxaliplatin, and
vehicle groups were 40.40 ± 1.84 g, 41.37 ± 1.49 g, and
41.13 ± 2.62 g, respectively. Cisplatin and oxaliplatin-
treated mice maintained similar muscle strength com-
pared to the controls throughout treatment (P  > 0.05,
ANOVA). At week three, mean grip strength for cisplatin,
oxaliplatin, and vehicle groups were 39.62 ± 2.28 g, 41.68
± 1.84 g, and 42.41 ± 2.10 g, respectively. At week six,
mean grip strength for cisplatin, oxaliplatin, and vehicle
groups were 39.83 ± 2.40 g, 41.00 ± 1.74 g, and 41.28 ±
1.76 g, respectively. At week eight, mean grip strength for
cisplatin, oxaliplatin, and vehicle groups were 41.44 ±
1.60 g, 42.07 ± 1.23 g, and 40.03 ± 2.02 g, respectively.
Oxaliplatin-treated mice develop cold hyperalgesia in the 
hind paw
Cold pain is a common feature of acute oxaliplatin neu-
ropathy, which was readily detected by the cold plate
assay. At baseline, there was no significant difference in
the response to cold stimulus at -4.2°C between groups,
(Fig. 3, P > 0.05, two-way ANOVA). After the first treat-
ment cycle, oxaliplatin -treated mice had a significant (2-
fold) increase in the number of paw lifts compared the
vehicle-treated controls (30.45 ± 4.27 vs 15.08 ± 2.41, *P
< 0.05, ANOVA), and a similar increase in cold hypersen-
sitivity was observed after the second treatment cycle
(32.43 ± 6.45 vs 10.84 ± 1.80, ***P < 0.001, two-way
ANOVA). This cold hyperalgesia persisted to six weeks
(22.00 ± 2.80 vs 6.20 ± 1.50, *P < 0.05, two-way ANOVA)
and gradually returned to baseline at week eight (Fig. 3, P
> 0.05, two-way ANOVA). Although there were more paw
lifts to cold stimuli in the cisplatin group, this difference
was not statistically significant compared to controls (Fig.
3.  P  > 0.05, two-way ANOVA). The variability of cold
hyperalgesia between week 6 and 8 illustrated the acute
neurotoxic effect of oxaliplatin drug treatment. Behavioral
evidence for the early onset of cold hypersensitivity was
Cisplatin-treated mice show reduced exploratory activity fol- lowing each drug treatment cycle Figure 2
Cisplatin-treated mice show reduced exploratory 
activity following each drug treatment cycle. Data rep-
resent the mean ± S.EM of 6 mice, **P < 0.01; ***P < 0.001, 
two-way ANOVA followed with post hoc analysis.
Oxaliplatin-treated mice exhibit cold hyperalgesia to cold  plate assay Figure 3
Oxaliplatin-treated mice exhibit cold hyperalgesia to 
cold plate assay. Oxaliplatin-treated mice show increased 
number of paw lifts to -4.2°C noxious cold stimulus at weeks 
1, 3 and 6. Data represent the mean ± S.EM of 7 mice, *P < 
0.05; ***P < 0.001, two-way ANOVA followed with post hoc 
analysis.Molecular Pain 2009, 5:9 http://www.molecularpain.com/content/5/1/9
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also reported in rats, which were given to either low or
high doses of oxaliplatin [32]. With sustained use of oxali-
platin drug treatment, neurotoxic effects could manifest as
hypoalgesia, a characteristic pain symptoms seen in
patient, however, this remains to be examined in mice.
Cis- and oxaliplatin-treated mice exhibit mechanical 
allodynia in the hind paw
Platinum drug treatment consistently evoked marked
mechanical allodynia, although enhanced mechanical
nociception was greater for cisplatin than for oxaliplatin-
treated mice (Fig. 4). At baseline, there was no significant
difference in response to punctuate mechanical stimuli
(von Frey assay) between groups (Fig. 4, P > 0.05, two-way
ANOVA). However, after completion of two treatment
cycles, both cisplatin and oxaliplatin groups exhibited sig-
nificant 45% and 25% decreases in paw withdrawal
thresholds compared to the vehicle group 2.43 ± 0.09 g
and 3.19 ± 0.12 g, versus 4.36 ± 0.56 g, respectively (Fig.
4, ***P < 0.001 and ***P < 0.001, two-way ANOVA).
While the cisplatin group continued to show significant
28% and 14% decreases in paw withdrawal thresholds
compared to the vehicle group at weeks six and eight,
respectively (***P  < 0.001 and *P  < 0.05, two-way
ANOVA), however, no statistically significant change was
observed with the oxaliplatin group (P > 0.05, two-way
ANOVA). These findings are consistent with current
observations where the neurotoxicity appeared to be less
severe with oxaliplatin treatment.
Cisplatin-treated mice exhibit increased sensitivity to 
thermal stimuli in the hind paw and the tail
Clear and robust heat evoked responses were observed in
two behavioral heat assays (radiant heat and tail immer-
sion) from cisplatin-treated mice demonstrating that cis-
platin induces thermal hyperalgesia in this model. In
contrast, no such heat responses were observed for oxali-
platin-treated mice. Cisplatin induced significant thermal
nociception to hind paw (Fig. 5), which paralleled with
the mechanical nociception as previously observed in Von
Frey assay (Fig. 4). At baseline, there was no significant
difference between groups in paw withdrawal responses
to noxious heat stimuli (Fig. 5, P  > 0.05, two-way
ANOVA). After two cycles of drug treatment, the cisplatin
group developed a significant 37% decrease in paw with-
drawal latencies compared to the vehicle group (4.29 ±
0.36 s vs 6.85 ± 0. 0.36 s, ***P < 0.001, two-way ANOVA).
The cisplatin group continued to exhibit significant 30%
and 18% decreases in paw withdrawal latencies compared
to the vehicle group at weeks six and eight, respectively
(***P  < 0.001 and *P  < 0.05, two-way ANOVA).
Although there was a decrease in paw withdrawal latency
in the oxaliplatin group compared to the vehicle group,
the difference was not significant after 3, 6 or 8 weeks (P
> 0.05, two-way ANOVA).
In the tail immersion assay, there was no significant differ-
ence in response to noxious heat stimuli between treat-
ment groups at baseline (Fig. 6, P  > 0.05, ANOVA).
However, after two cycles of drug administration, the cis-
platin group exhibited highly significant thermal hyperal-
Cis- and oxaliplatin-treated mice develop mechanical allody- nia to von Frey filament assay Figure 4
Cis- and oxaliplatin-treated mice develop mechanical 
allodynia to von Frey filament assay. Cis- and oxalipla-
tin-treated mice show decreased response thresholds to 
punctate mechanical stimuli at weeks 3, 6, and 8. Data repre-
sent the mean ± S.EM of 7 mice, *P < 0.05; ***P < 0.001, two-
way ANOVA followed with post hoc analysis.
Cisplatin-treated mice exhibit thermal hyperalgesia to radiant  heat assay Figure 5
Cisplatin-treated mice exhibit thermal hyperalgesia 
to radiant heat assay. Cisplatin-treated mice show 
decreased response withdrawal latencies to noxious thermal 
stimuli at weeks 3, 6, and 8. Data represent the mean ± S.EM 
of 7 mice, *P < 0.05; ***P < 0.001, two-way ANOVA fol-
lowed with post hoc analysis.Molecular Pain 2009, 5:9 http://www.molecularpain.com/content/5/1/9
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gesia compared to the vehicle group, and this heat
hypersensitivity persisted with a 46% decrease in tail flick
latency at week four (1.83 ± 0.23 s vs 3.39 ± 0.19 s, ***P
< 0.05, ANOVA), and a 36% decrease in tail flick latency
at week six (2.15 ± 0.14 s vs 3.36 ± 0.33 s, *P < 0.05,
ANOVA). The lower level of thermal hyperalgesia starting
at week 8 depicted the gradual return to baseline of heat
response for both paws (Fig. 5) and tail (Fig. 6) in cispla-
tin treated mice, which indicated the threshold cisplatin
dose used in our study. This recovery of responsiveness to
heat stimuli may be unlikely to occur with repeated cispl-
atin administration or higher accumulative doses. Similar
observations were found in rats which were given a range
of low to high doses of cisplatin [33]. A different pattern
of heat evoked response was observed with oxaliplatin.
Although there was a decrease in tail flick latency in the
oxaliplatin group compared to the vehicle group, the dif-
ference was not significant at weeks six and eight (P >
0.05, ANOVA).
Discussion
Patients treated with the platinum compounds cisplatin
and oxaliplatin develop dose-related sensory changes.
Pain is prominent for both, but cold-induced allodynia or
hyperalgesia is a distinctive feature of oxaliplatin treat-
ment [22]. In the present study, we demonstrated that
after two treatment cycles of cisplatin and oxaliplatin in
mice, different patterns of hyperalgesia emerged for the
two drug treatments. Cisplatin-treated mice developed
chronic neuropathy with heat hyperalgesia and mechani-
cal allodynia. In contrast, oxaliplatin-treated mice only
exhibited acute neuropathy with cold hyperalgesia and
mechanical allodynia. These results establish the mouse
as a reliable and objective model that can be used to quan-
titatively assess neuropathic pain behaviors associated
with platinum-based drugs.
The intraperitoneal injection of 23 mg/kg cisplatin and 30
mg/kg oxaliplatin approximates human therapeutic doses
relative to body weight. In these experiments, treatment
doses of cisplatin and oxaliplatin had comparable effects
in rodent cell culture models [34]. With these doses, we
were able to detect nociceptive responses without causing
major deterioration in the general health of the mice. Our
previous studies have demonstrated that higher doses of
cisplatin result in renal failure and decreased survival [35].
Both platinum drugs also had similar temporal effects on
the exploratory activity and body weight of the mice.
These were rapidly reversed after cessation of treatment.
These observations also confirmed that the increased
behavioral responses to cold or heat stimuli could not be
explained by an overall increase in locomotor activity.
Since cold pain is one of the hallmark symptoms of oxali-
platin acute neurotoxicity, we also studied the response to
cold stimuli using a cold plate assay. Cold plate testing
with a range of temperature from -5°C to 15°C has been
used to study cold allodynia and hyperalgesia in labora-
tory rats [36,37]. We found that the oxaliplatin-treated
mice exhibited increased responses in the cold plate test at
-4.2°C shortly after the first drug cycle. A more robust
response was observed after the second drug cycle at week
3. Residual cold hyperalgesia lasted two weeks after the
last dose of oxaliplatin. This cold induced hyperalgesia
mimics the acute, painful dysesthesia reported by more
than 80% of patients treated with oxaliplatin [38]. While
some of the mice in the cisplatin group also developed
increased cold hypersensitivity, these changes were not
significant. Similar to our findings, Ling et al found that
after a total dose of 18 mg/kg oxaliplatin administered
intravenously over four and half weeks, rats developed
cold hyperalgesia to tail immersion at 4°C and mechani-
cal allodynia in the von Frey assay [39]. After a single
intraperitoneal injection, these authors found that rats did
not develop heat hypersensitivity at 46°C (tail immersion
test), but developed cold hypersensitivity at 4°C and
10°C, respectively [32].
We observed that hyperalgesia to thermal stimuli per-
sisted for up to five weeks post treatment for the cisplatin-
treated mice. This heat response was consistent in two dif-
ferent thermal stimulus assays. We also observed that the
pattern of onset and progression of the heat hyperalgesia
was similar to the mechanical allodynia in cisplatin-
treated mice, which reflected the consistency of the radi-
ant heat and von Frey assays. Although oxaliplatin-treated
Cisplatin-treated mice developed thermal hyperagesia to tail  immersion assay Figure 6
Cisplatin-treated mice developed thermal hyperage-
sia to tail immersion assay. Cisplatin-treated mice show 
decreased response tail flick latencies to noxious thermal 
stimuli at weeks 4 and 6. Data represent the mean ± S.EM of 
7 mice, *P < 0.05; ***P < 0.001, two-way ANOVA followed 
with post hoc analysis.Molecular Pain 2009, 5:9 http://www.molecularpain.com/content/5/1/9
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mice showed a slight decrease in heat pain threshold, this
reduction was not statistically significant. However, they
responded significantly to punctate mechanical and cold
stimuli; this transient behavioral alteration appeared to be
similar to responses frequently observed in oxaliplatin-
treated patients.
While there is some agreement about altered nociceptive
responses to heat stimuli following chronic cisplatin treat-
ment in animal models [33], there have been some incon-
sistencies. Many factors could influence pain behavioral
outcomes including different species, genetic strain, gen-
der, and type of pain assay [40]. The use of rats and differ-
ent strains of mice, higher drug dose, and varying heat
intensities from previous studies might contribute to dif-
ferent results [41-44].
The chemotherapeutic mechanisms of platinum agents
are still not fully understood. Similarly, the reasons for the
selective neurotoxicity of platinum compounds and the
distinctive, reversible cold sensitivity induced by oxalipla-
tin are not fully understood. Sensory neurons may be
more vulnerable to platinum drugs because they are not
protected by the blood brain barrier. We have shown that
DRG neurons accumulate high levels of Pt-DNA adducts
in a time-dependent manner following cis- and oxalipla-
tin exposure [34,45]. The amount of platinum binding to
DNA is comparable to or exceeds levels known to induce
toxic effect to cancer cells. This platinum binding has been
shown to induce neurons to enter the cell cycle and
undergo apoptosis [46].
Oxaliplatin is known to cause greater toxic effects with less
platinum-DNA binding in cancer cells [47-50]. We found
a consistently lower level of Pt-DNA adducts in oxalipla-
tin treated DRG cells; although it was still ten times higher
than levels bound to tumor cell DNA [45]. The lower lev-
els of Pt-DNA adduct correlated with less cell death
induced by oxaliplatin [34]. These findings are consistent
with current observations where the neurotoxicity
appeared to be less severe with oxaliplatin treatment,
resulting in only transient mechanical and cold hypersen-
sitivity. While the mechanism responsible for this acute
neuropathy remains unclear, functional alterations of
voltage-gated Na+ [51,52] and glutathione S-transferase
polymorphisms have also been associated with this oxali-
platin neuropathy [53].
Cisplatin and oxaliplatin treatment have not been shown
to induce neuronal loss in peripheral nerves in rodent
models [54-57]. This absence of cell death is reflected in
the reversibility of nociceptive behaviors seen in treated
mice. Animals with experimentally induced neuropathies
are frequently seen to have little overt morphological evi-
dence of damage to their peripheral nerves [54-57]. Cispl-
atin treatment has been shown to result in minimal
axonal degeneration or minimal loss of epidermal fibers
in mice [42]. In this study, cisplatin and oxaliplatin-
treated mice exhibited no significant loss of fiber density
in intraepidermal nerve testing compared to controls
(data not shown). However, sensory impairment is
known to associate with decrease in nerve conduction
velocity in animal studies after cisplatin [41,42,44,58]
and oxaliplatin drug treatments [56,59].
Changes in neuropeptide expression have been demon-
strated in rodent models. Substance P and Calcitonin
Gene Related Peptide in pain fibers have been shown to
be altered following cis- and oxaliplatin treatment
[59,60]. These observed cellular changes could lead to
increased activity and hypersensitivity of nociceptive neu-
rons, which may contribute to the spontaneous pain and
pain hypersensitivity that are characteristic of neuropathic
pain. Future studies dissecting the mechanisms by which
these changes are activated could provide further under-
standing of the pathophysiological mechanism of plati-
num-induced painful neuropathy.
Conclusion
The present study suggests that mice may be an excellent
animal model in which to examine the role of platinum
drugs, and their neurotoxic effects on peripheral nervous
systems involved in the induction of pain. These mouse
models may also be useful in examining potential thera-
peutic approaches in treating painful neuropathy associ-
ated with platinum drugs in humans.
Methods
This study was conducted with the approval of the Mayo
Clinic Animal Care and Use Committee, and is in compli-
ance with regulations of the National Institutes of Health
and ethical guidelines of the International Association for
the Study of Pain [61]
Experimental animals and drugs treatment
Male C57BL6J mice 9–10 weeks of age were obtained
from Jackson Lab (Maine). Mice were ordered at least two
weeks prior to study to allow for acclimatization. Mice
were housed four to a cage in an enriched environment
that included a carton hut, bedding blocks, and wood
chewing blocks. Mice were closely monitored daily for
signs of fighting and aggression during the initial week
after arrival. Fighting often occurs in group housing of
male mice that are not littermates due to dominance hier-
archies. Once the dominant mouse was identified and
caged individually, the remaining mice were housed
together without signs of fighting. This approach has been
shown to be both humane and minimizes injury and
aggression [62]. More importantly, it also avoids stress-
induced analgesia that could confound basal nociceptiveMolecular Pain 2009, 5:9 http://www.molecularpain.com/content/5/1/9
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sensitivity [63]. Following two weeks of habituation to the
colony, mice were trained with various behavioral testing
apparatus for an additional week prior to entering to the
study. Mice were 13–14 weeks old and weight was 24–26
g, when the study began. All mice had free access to water
and food and were exposed to a standard light cycle of 12
h on and 12 h off.
Oxaliplatin (Sigma-Aldrich, St. Louis, MO) was dissolved
in sterile distilled water (1 mg/ml) and prepared each day.
Pharmaceutical grade cisplatin (1 mg/ml) was obtained
from Bristol-Myers Squibb Company (Princeton, NJ).
After habituation to the test environment and baseline
measurements of pain sensitivity, mice were randomized
to three treatment groups of either cisplatin (2.3 mg/kg),
oxaliplatin (3.0 mg/kg), or vehicle (0.9% saline). Treat-
ment doses were based on preliminary dose-escalation
studies to determine the threshold concentration produc-
ing a measurable difference in pain response between
drug-treated and naïve mice (data not shown). Mice were
treated with daily intraperitoneal (i.p.) injection for 5
days, followed by 5 days of rest, for two cycles. Total
cumulative doses of 23 mg/kg cisplatin and 30 mg/kg
oxaliplatin over a total of ten injections were used. These
doses and dosing schedules are comparable to patient
treatment regimens. A total of 200 μl solution was used
for each injection, oxaliplatin solution was prepared with
5% dextrose (Baxter Healthcare, Deerfield, IL), and cispl-
atin solution was prepared with 0.9% saline (Baxter
Healthcare, Deerfield, IL). Injections were performed
between the hours of 0900 and 1100.
Evaluation of general toxicity
Mouse body weight was determined at baseline, before
each drug administration and every week up to 8 weeks.
In addition, mice were also examined daily for evaluation
of general health including observation for signs of hair
loss, piloerection, general gait weakness, condition of the
hind paws and tail skin, and gastrointestinal disorders.
Ear cavity temperature was measured using an infrared
thermometer (model IRT303HACCP, National Product,
MD) at baseline and after weeks 1, 3, 6, and 8 prior to per-
forming the behavioral tests. Core body temperature was
measured using a rectal probe (Thermalert TH-5 and
TCAT-1A Controller, Physitemp Instruments, Inc) at base-
line and after weeks 1, 3, and 6 in two mice from each
drug treatment group after brief anesthesia with isoflu-
rane.
The nephrotoxicity of cisplatin and oxaliplatin was
assessed by blood urea nitrogen (BUN) levels in samples
collected at the end of the 3-week drug treatment. Based
on normal mouse BUN values (8–33 mg/dl according to
normal reference laboratory values from Research Animal
Resources at the University of Minnesota-http://
www.ahc.umn.edu/rar/refvalues.html; values as reported
for normal untreated C57BL/6 mice [64]), BUN levels >
40 mg/dL were used as an indication of developing neph-
rotoxicity.
Behavioral testing
The testing protocol is summarized in Table 1. The order
of testing was designed to insure that the least stressful test
was done first and to minimize the influence of one test
on the next test. After a 2-week acclimation, the mice were
Table 1: Order and time sequence of testing sessions
Testing Session Treatment i.p. Activity Assay Grip Strength Cold Plate Von Frey Radiant Heat Tail Immersion
Habituation Week XX X X
Baseline XX X X X XX
Week 1 daily i.p. injection X X X X X X
Week 2 5 days rest X X
Week 3 daily i.p. injection X X X X X
Week 4 X
Week 6 XX X X XX
Week 8 XX X X XX
Week 10 XMolecular Pain 2009, 5:9 http://www.molecularpain.com/content/5/1/9
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trained five times over one week with the specific training
protocols to familiarize them with testing procedures
prior to entering the study. For the von Frey and paw radi-
ant heat test, mice were allowed to run freely in the appa-
ratus for 20 min before beginning the test. For the tail
immersion test, each mouse was loosely wrapped in a par-
tially rolled, moist paper towel for one min; the practice
episode was repeated for 3–4 times. For the grip strength
test, each mouse was guided for 5 min to pull the trapeze
of the grip strength meter 3–4 times. No training was used
for the cold plate apparatus. All behavioral tests were car-
ried out in groups of 4–6 experimental mice at baseline,
after completion of each drug treatment cycle at weeks 1
and 3, and follow up evaluation at weeks 6 and 8. All
behavioral tests were conducted at room temperature
(25°C) and between the hour of 0900 and 1600 by one
experimenter who was blinded to the drug treatment con-
dition.
Activity monitoring
Monitoring of locomotor activity was carried out at base-
line, during drug treatment at weeks 1, 2, 3, and after treat-
ment at weeks 6, 8, and 10 using VersaMax Animal
Activity Monitors (AccuScan Model RXYZCM-16, Colum-
bus, OH). The activities of six mice were simultaneously
evaluated in six individual open chambers. Mice were
allowed to run freely for 5 min prior to behavioral record-
ing for 20 min in the open chamber made of a Plexiglas
box (42 × 42 × 30 cm) with wood chip bedding. The Ver-
saMax monitor has infrared sensors located every 2.54 cm
along the perimeter (16 infrared beams along each side)
and 2.5 cm above the floor. Although the VersaMax mon-
itor collects information in 21 behavioral categories, we
only analyzed distance traveled collected in 1-min inter-
vals, collapsed into 10 2-min blocks, averaged and pre-
sented as group means ± SEM Data were analyzed by a
VersaMax Analyzer (AccuScan Model CDA-8, Columbus,
OH).
Grip strength test
Grip strength was measured using a grip strength meter
(Stoelting, Wood Dale, Il) as previously described [65].
The grip strength meter consists of a force transducer with
digital display and a metal plate with a trapeze. Each
mouse was placed on the plate and was pulled by its tail
with increasing force until it was unable to grasp the tra-
peze and the grip was broken. The instrument digitally
captures and displays the peak pull-force achieved. Muscle
strength was defined as the peak weight (g) indicated on
the display. The value was determined individually as the
mean of three trials and presented as group mean ± SEM
Cold plate assay
Temperatures ranging from -5°C to 4°C at 1°C intervals
were used to examine the threshold for cold hyperalgesia
in mice. We found that measuring latency to first paw lift
was difficult and highly variable. Greater reproducibility
was obtained when counting the number of paw lifts in a
defined period. When temperature ranged from 0°C to
4°C, naive mice showed few paw lifts (data not shown).
However, when the temperature was lowered from -2°C
to -5°C, the number of paw lifts for naïve mice increased
(data not shown). In preliminary dosing studies, oxalipl-
atin-treated mice developed significant cold hyperalgesia
between -5°C and -3°C, (data not shown). Temperature
setting at -4.2°C was used for cold plate testing since there
was no tissue damage and the least variability in responses
was observed at this temperature (compared with -3°C).
The final conditions used were with the Peltier-cooled
cold plate preset at -4.2° ± 0.2°C. A temperature sensor
was placed directly on the surface of the metal plate to
insure accurate temperature reading (TECA, Chicago, IL).
For each cold testing session, mice were brought to the
testing room and allowed to acclimate for 10 min prior to
being individually placed onto the cold metal surface
enclosed within a clear plexiglass barrier of 8 cm W × 14
cm D × 14 cm H with a top cover. To insure the accuracy
of paw lift counting, we videotaped each cold plate testing
session using a video camcorder (Sony DCR-PC1000) and
replayed in slow motion. The total number of brisk lifts of
either hind paw or jumping was counted as the response
to cold hyperalgesia. Movements associated with locomo-
tion were distinct, involving coordinated movement of all
four limbs and these were excluded. Mice were only tested
once on any given test day to avoid any possible anes-
thetic or tissue damage effects that could be produced by
repeated exposure to a cold surface. A maximum cut off
time of 5 min was used to prevent tissue damage. Three
separate trials were carried out on three separate days at
base line and two separate trials during and after drug
treatment at weeks 1, 3, 6, and 8 were averaged and pre-
sented as the mean number of paw lifts.
Von Frey filament assay
For the assessment of mechanical allodynia, an Ugo Basile
Dynamic Plantar Aesthesiometer (Stoelting, Wood Dale,
Il) using the von Frey filament principle was used [66].
Mice were placed under clear plastic boxes above a wire
mesh floor that allowed full access to the paws. Acclima-
tion and exploratory behavior were observed for up to two
h until mice became calm and close to motionless. The
operator then placed the touch stimulator apparatus
under each mouse's hind paw and positioned the cali-
brated metal filament below the target area of the hind
paw. After pressing the start key, an electrodynamic actua-
tor of the apparatus lifts the metal filament (diameter of
0.5 mm). The filament touches the plantar surface and
exerts a continuous vertical force of 0 to 5 g over a 10 sec
interval until the hind paw withdraws and activates a stop
signal. The instrument automatically registered the weightMolecular Pain 2009, 5:9 http://www.molecularpain.com/content/5/1/9
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intensity threshold in g that triggered paw withdrawal.
Each hind paw was tested alternately with an interval of 5
min for four trials. Paw movement associated with loco-
motion or weight shifting was not counted as withdrawal
responses. Paw withdrawal threshold of eight trials from
both hind paws of each mouse were averaged and
recorded as mean ± SEM.
Radiant heat assay
For the assessment of thermal hyperalgesia, a Hargreaves'
test [67] was conducted using a Plantar Ugo Basile appa-
ratus (Stoelting, Wood Dale, Il). Mice can move freely in
this apparatus on an elevated glass surface with plastic
boxes above as the top cover. Mice are given a two h accli-
mation period prior to testing until they become calm and
motionless. A calibrated infrared light source of high
intensity was applied perpendicular on the plantar surface
of each mouse's hind paw. The rising temperature on the
bottom of the hind paw caused the mouse to move its
paw; the change in paw position alters reflected light and
stops the timer. Latency to paw withdrawal was automat-
ically recorded for each trial. If the mouse did not with-
draw its hind paw within 15 s, the testing trial terminated
to prevent tissue damage and 15 s was recorded. Each
hind paw was tested alternately with an interval of 5 min
for four trials. Paw withdrawal latency of eight trials from
both hind paws of each mouse was averaged and recorded
as mean ± SEM.
Tail immersion assay
For assessment of tail thermal hyperalgesia, a tail immer-
sion test was conducted as previously described with
modifications [68]. For each testing session, mice were
brought to the testing room and each was individually
acclimatized three to four times in a moist paper towel for
a minute duration without tail immersion. Next, each
mouse was swiftly and gently wrapped in a slightly moist
paper towel and held in the investigator's hand with min-
imal restraint to allow the distal one-third of the tail to be
immersed in a water bath. The water bath was preset at
50.5° ± 0.5°C and the temperature was verified with an
independent extra temperature sensor. Only when the
mouse was calm and its tail was relaxed, was the next step
of tail immersion pursued. If the mouse became agitated,
it was unwrapped and the testing protocol restarted.
Latency to vigorous tail flick was recorded during three tri-
als separated by at least 30 min, and three trials were aver-
aged and presented as mean ± SEM. Cutoff time was set at
20 s, after which mouse was removed regardless of behav-
ioral response.
Statistical analyses
All data are expressed as mean ± standard error of the
mean (SEM). Results were illustrated and analyzed using
Graph pad Prism version 4 (Graphpad Software, San
Diego, USA). Statistical analyses were performed using
two-way ANOVA with drug treatments and time as inde-
pendent variables to examine for the differences in
responses across treatment groups. Follow-up analysis
was conducted using the Bonferroni test. A P value of less
than 0.05 is considered as statistically significant.
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